Author: Chang Chen; Jianying Huang; Zhenshun Cheng; Jianyuan Wu; Song Chen; Yongxi Zhang; Bo Chen; Mengxin Lu; Yongwen Luo; Jingyi Zhang; Ping Yin; Xinghuan Wang
Title: Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial Document date: 2020_3_20
ID: 14he8n3u_45
Snippet: Compared to Arbidol, Favipiravir does not significantly improve clinical recovery rate of Day 7. Favipiravir is associated with significantly shortened latency to relief for pyrexia and cough. Antiviral-associated adverse effects of Favipiravir are mild and manageable......
Document: Compared to Arbidol, Favipiravir does not significantly improve clinical recovery rate of Day 7. Favipiravir is associated with significantly shortened latency to relief for pyrexia and cough. Antiviral-associated adverse effects of Favipiravir are mild and manageable.
Search related documents:
Co phrase search for related documents- adverse effect and recovery rate: 1
- Arbidol compare and cough pyrexia: 1
- Arbidol compare and cough pyrexia relief: 1
- Arbidol compare and recovery rate: 1
- cough pyrexia and recovery rate: 1, 2, 3, 4
- cough pyrexia relief and recovery rate: 1, 2
- recovery rate and significantly shorten: 1, 2
Co phrase search for related documents, hyperlinks ordered by date